|
China Medical Technologies, Inc. (NASDAQ:(CMED )) is a China-based medical device company that develops, manufactures and markets advanced in-vitro diagnostic ("IVD") products using Enhanced Chemiluminescence ("ECLIA") technology, Fluorescent in situ Hybridization ("FISH") technology and Surface Plasmon Resonance (“SPR”) technology to detect and monitor various diseases and disorders.〔http://www.chinameditech.com/eng/about/profile.htm〕 In February 2012, the company's shares moved from the NASDAQ to the pink sheet in the United States.〔http://www.nasdaq.com/symbol/cmed〕 The company is in default due to failure to pay interest to bondholders.〔http://www.chinascopefinancial.com/news/post/7492.html〕 ==Business== The ECLIA business, which consists of ECLIA analyzer and reagent kits, is an IVD system based on ECLIA technology. The reagent kits are used to detect various thyroid disorders, diabetes, hepatitis, Down syndrome, liver fibrosis, disorders related to reproduction and growth and various types of tumors. The FISH business, which consists of FISH imaging analyzer and FISH probes, is a molecular diagnostic system based on FISH technology. FISH probes are molecular diagnostic reagents used with FISH imaging analyzer for the prenatal and postnatal diagnosis of various genetic diseases and for the early detection and prognosis of various cancers. THE SPR business, which consists of SPR system and HPV-DNA chips, is a molecular diagnostic system based on SPR technology. The HPV-DNA chips are label-free DNA chips for the diagnosis of HPV infection and genotyping of HPV. 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「China Medical Technologies」の詳細全文を読む スポンサード リンク
|